Vaginal, Urethral, Uterine Patents (Class 424/430)
-
Patent number: 5744161Abstract: Compositions and methods for the improvement of gastrointestinal absorption and systemic utilization of nutrients and nutritional supplements, wherein the compositions comprise a minimum of 98% of pure alkaloid piperine. The method comprises oral, topical, or parenteral administration of the compositions of the invention. A new process for the extraction and purification of piperine is also disclosed.Type: GrantFiled: October 30, 1995Date of Patent: April 28, 1998Assignee: Sabinsa CorporationInventors: Muhammed Majeed, Vladimir Badmaev, Ramaswamy Rajendran
-
Patent number: 5741525Abstract: Gelled vaginal pharmaceutical composition containing:a water-soluble bioadhesive polymer, a peroxide source and pH buffer wherein the composition has a pH between about 3.0 and about 6.0; and methods of using same.Type: GrantFiled: October 24, 1995Date of Patent: April 21, 1998Assignee: Marshall University Research CorporationInventor: Bryan Larsen
-
Patent number: 5725870Abstract: Vaginal application of cysteamine, cystamine, phosphocysteamine, or a pharmaceutically acceptable salt thereof is effective for contraception.Type: GrantFiled: January 16, 1996Date of Patent: March 10, 1998Inventor: Jess G. Thoene
-
Patent number: 5702716Abstract: The invention is directed to an improved system for controlled release of biologically active materials and to a liquid composition for its formation. The liquid composition is composed of a thermoplastic polymer, rate modifying agent, bioactive material and organic solvent. The liquid composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of biologically active substances to tissues or organs.Type: GrantFiled: June 2, 1993Date of Patent: December 30, 1997Assignee: Atrix Laboratories, Inc.Inventors: Richard L. Dunn, Arthur J. Tipton
-
Patent number: 5703200Abstract: This invention provides various copolymers comprising a first repeating unit of the chemical formula: ##STR1## in which R.sub.1 and/or R.sub.2 are alkyl groups and a second repeating units generally having the chemical formula: ##STR2## and combinations of two or more thereof wherein R is a hydrogen atom or a methyl group and the first repeating unit is less than 45 weight percent of the total weight of the copolymer. This invention also relates to use of these copolymers in the fabrication of absorbable surgical devices such as sutures and as coatings for medical devices. Additionally, described are blends and polyoxaesters containing the first repeating unit.Type: GrantFiled: March 15, 1996Date of Patent: December 30, 1997Assignee: Ethicon, Inc.Inventors: Rao S. Bezwada, Steven C. Arnold, Constance Ace
-
Patent number: 5700583Abstract: The present invention describes a crosslinked aliphatic polyoxaesters containing amines and/or amido groups and blends thereof with other polymers that may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The crosslinked aliphatic polyoxaesters of the present invention is formed from an aliphatic polyoxaester having a first divalent repeating unit of formula I:?O--C(O)--C(R.sub.1)(R.sub.2)--O--(R.sub.3)--O--C(R.sub.1)(R.sub.2)--C(O)-- !Iand a second repeating unit of the formula:?--O--R.sub.12 --!.sub.U, XVIand optionally a third repeating unit with a formula selected from the group consisting of:?--O--R.sub.4 --!.sub.A, II?--O--R.sub.5 --C(O)--!.sub.B, III(?--O--R.sub.5 --C(O)!.sub.P --O--).sub.L G XIand combinations thereof wherein R.sub.12 contains an internal amine or internal amide group wherein the aliphatic polyoxaester has been crosslinked.Type: GrantFiled: November 6, 1996Date of Patent: December 23, 1997Assignee: Ethicon, Inc.Inventors: Dennis D. Jamiolkowski, Rao S. Bezwada
-
Patent number: 5700783Abstract: A method for treating urinary incontinence consisting of injecting human fibrin glue at or near the bladder neck until the urethral outflow resistance is restored. Human fibrin glue is the reaction product of human fibrinogen and thrombin in the presence of calcium chloride as catalyst.Type: GrantFiled: April 24, 1995Date of Patent: December 23, 1997Assignee: Angelo PintoInventor: Angelo Pinto
-
Patent number: 5700478Abstract: Water-soluble pressure-sensitive adhesives include a water-soluble polymer that is made tacky at room temperature by addition of a water-soluble plasticizer that is miscible with the polymer. Suitable polymers are solid at room temperature; and have a hydrophilicity as measured by water uptake greater than about 25%; they are liquid at room temperature and have a boiling point higher than about 80.degree. C. The adhesives according to the invention may conveniently be provided in dry film form. Preferred water-soluble pressure-sensitive adhesives of the invention adhere both to mucosal surfaces and to a variety of materials that may constitute a part of a device or prosthesis to be held in a body cavity that has a mucosal lining. Also, a laminated device for the controlled release of a substance within a mucosa-lined body cavity includes the substance dissolved or dispersed in either or both of a water-soluble pressure-sensitive adhesive layer and optionally one or more water-soluble polymer layers.Type: GrantFiled: August 3, 1995Date of Patent: December 23, 1997Assignee: Cygnus, Inc.Inventors: James E. Biegajski, Subbu S. Venkatraman, Ann M. Scott
-
Patent number: 5698214Abstract: Monilial Vulvovaginitis is treated by application of a composition containing one or more substances which inhibit glucose transfer into cells and cell metabolism. The composition of the invention is conveniently combined with a suitable carrier such as a non-aqueous gel and other therapeutically useful components.Type: GrantFiled: February 24, 1992Date of Patent: December 16, 1997Inventors: Harry H. Leveen, Eric G. Leveen, Robert F. Leveen
-
Patent number: 5698213Abstract: The present invention describes a new crossslinkable and crosslinked aliphatic polyoxaesters and blends thereof that may be used to produce hydrogels, surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The invention also contemplates a process for producing these polyesters. The crosslinked aliphatic polyoxaesters of the present invention are formed from an aliphatic polyoxaester a first divalent repeating unit of formula I:?O--C(O)--C(R.sub.1) (R.sub.2)--O--(R.sub.3)--O--C(R.sub.1) (R.sub.2)--C(O)--! Iand a second repeating unit selected from the group of formulas consisting of:?--O--R.sub.4 --!.sub.A, II?--O--R.sub.5 --C(O)--!.sub.B, IIIand(?--O--R.sub.5 --C(O)!.sub.P --O--).sub.L G XIand combinations thereof. These aliphatic polyoxaesters may be blended with other polymers which are preferably biocompatible.Type: GrantFiled: November 6, 1996Date of Patent: December 16, 1997Assignee: Ethicon, Inc.Inventors: Dennis D. Jamiolkowski, Rao S. Bezwada
-
Patent number: 5696078Abstract: Peptides representing defined portions of the amino acid sequences of naturally occurring human and macaque histatins, modified peptides, expression vectors encoding these peptides, and compositions and methods for treatment of fungal infection are described. Some of the histatin-based peptides exhibit superior anti-fungal activity to native, intact histatins. Isolated, naturally occurring macaque histatins and peptide analogs are also described.Type: GrantFiled: May 16, 1995Date of Patent: December 9, 1997Assignee: The Trustees of Boston UniversityInventors: Frank G. Oppenheim, Tao Xu
-
Patent number: 5685872Abstract: Absorbent articles, such as catamenial tampons, for absorbing body fluids are disclosed which include an effective amount of a nitrogen containing compound to substantially inhibit the production of exotoxins by Gram positive bacteria. The compound is one or more nitrogen containing compounds having the general formula ##STR1## wherein R.sub.1, inclusive of the carbonyl carbon, is an alkyl group having 8 to 18 carbon atoms and R.sub.2 and R.sub.3 can be the same or different. Moieties R.sub.2 and R.sub.3 can be selected from hydrogen and an alkyl group having 1 to about 12 carbon atoms which may contain one or more substituent groups selected from ester, ether, amine, hydroxyl, carboxyl, carboxyl salts, sulfonate, sulfonate salts and mixtures thereof. The compound is effective in substantially inhibiting the production of TSST-1 and Enterotoxin-B from S. aureus bacteria.Type: GrantFiled: June 7, 1995Date of Patent: November 11, 1997Assignee: Kimberly-Clark Worldwide, Inc.Inventor: Rae Ellen Syverson
-
Patent number: 5667809Abstract: A method for preparing a pharmaceutical microdispersion exhibiting enhanced bioavailability, including the steps of providing a thermodynamically stable pharmaceutical composition comprising at least one lipophilic pharmaceutical agent incorporated in a physiologically acceptable liquid carrier, the liquid carrier comprising one or more lipophilic solvents such as fluorochemicals and preferably at least one nonfluorinated co-solvent, and combining the stable pharmaceutical composition with an amount of at least one miscible diluent sufficient to initiate phase separation of the lipophilic pharmaceutical agent from the pharmaceutical composition wherein a microdispersion of the pharmaceutical composition is formed. Also disclosed are microdisperse pharmaceutical compositions and kits for forming such compositions.Type: GrantFiled: June 7, 1995Date of Patent: September 16, 1997Assignee: Alliance Pharmaceutical Corp.Inventors: Leo A. Trevino, Luis A. Dellamary, Thomas E. Tarara, Jeffry G. Weers, Helen M. Ranney
-
Patent number: 5667492Abstract: The present invention provides a composition and use of a composition comprising a bioadhesive cross-linked polycarboxylic acid polymer formulation that enables the use of relatively low mounts of anti-STD infectants, such as N-9, to be used to prevent infection by STDs without causing the irritation to genital tissue that often accompanies higher doses of anti-STDs. The bioadhesive polymer maintains greater contact between the anti-STD agent and the infectant for a much greater period of time, enabling a lower concentration to act longer on the infectant, when compared to currently-available commercial applications containing N-9. Such delivery will enable a safe and non-irritating decrease in the risk of infection with STDs, including HIV.Type: GrantFiled: October 7, 1994Date of Patent: September 16, 1997Assignee: Columbia Laboratories, Inc.Inventors: William J. Bologna, Howard L. Levine
-
Patent number: 5662913Abstract: Antimicrobial metal-based compositions, which are photostable, non-staining, and which are easily absorbed into lipophilic matrices, contain silver cations, complexed by acyclic polyether polymers through the formation of a "host-guest relationship" where the acyclic polyether is the "host" and the silver cation is the "guest," wherein stabilization of this "host-guest relationship" is accomplished through the use of excess anions. The compositions are useful for topical treatment of infections caused by bacteria, fungus and viruses in humans and animals and for treating medical devices, foams and adhesives to impart infection-resistance.Type: GrantFiled: July 1, 1994Date of Patent: September 2, 1997Inventor: Christopher C. Capelli
-
Patent number: 5656628Abstract: This invention relates to the use of L-acylcarnitine for the preparation of a drug and a technique for relieving the disease symptoms appearing in AIDS by administering an L-acylcarnitine. The invention furthermore relates to a drug for this purpose, characterized in content by L-acylcarnitine as active principle. The preferred L-acylcarnitine is L-acetylcarnitine.Type: GrantFiled: December 27, 1994Date of Patent: August 12, 1997Assignee: ZW Biomedical Research AGInventors: Roger Weil, Laura Scandurra
-
Patent number: 5656283Abstract: This invention relates to a novel method of manufacturing a lyophilized suppository composition wherein said suppository is made in situ in an applicator cartridge.Type: GrantFiled: June 8, 1995Date of Patent: August 12, 1997Assignee: Ortho Pharmaceutical CorporationInventors: Barbara Brummer, Paul Swick, Martin Link, William Hart
-
Patent number: 5650192Abstract: The invention relates to a muco-adherent, soluble device for administering active ingredients, a method of using said device, and an improved method of manufacturing said device using a continuous, enclosed mixing device capable of operating under pressure. The devices of the invention, which comprise a lyophilized foam and an active ingredient, have a dissolution time of at least about 8 hours, and preferably at least about 24 hours, and can provide for the sustained and/or controlled release of an active ingredient for up to about 24 hours.Type: GrantFiled: July 10, 1995Date of Patent: July 22, 1997Inventors: Peter Britton, Patricia Flanagan, William P. Hart, Deborah Linkin
-
Patent number: 5648377Abstract: The present invention relates to novel formulations and combinations of lipophilic and hydrophilic antioxidants and the use thereof in the therapeutic, foodstuff, dietetic, and cosmetic fields. These formulations are based on the use of carotenoids, procarotenoids and derivatives thereof with polyphenols of catechic structures. Said formulations, containing a lipophilic antioxidant and an hydrophilic one, can be used in the prevention of physiopatological conditions related at least partially to an over-production of free radicals, particularly aging, atherosclerosis and cancer.Type: GrantFiled: June 5, 1995Date of Patent: July 15, 1997Assignee: Indena S.p.A.Inventors: Ezio Bombardelli, Paolo Morazzoni
-
Patent number: 5648088Abstract: The present invention describes aliphatic polyoxaesters containing amines and/or amido groups and blends thereof with other polymers that may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The aliphatic polyoxaesters of the present invention have a first divalent repeating unit of formula I:[O--C(O)--C(R.sub.1)(R.sub.2)--O--(R.sub.3)--O--C(R.sub.1)(R.sub.2)--C(O)-- ]Iand a second repeating unit of the formula:[--O--R.sub.12 --].sub.u, XVIand optionally a third repeating unit with a formula selected from the group consisting of:[--O--R.sub.4 --].sub.A, II[--O--R.sub.5 --C(O)--].sub.B, III([--O--R.sub.5 --C(O)].sub.P --O--).sub.L G XIand combinations thereof wherein R.sub.12 contains an internal amine or internal amide group.Type: GrantFiled: March 5, 1996Date of Patent: July 15, 1997Assignee: Ethicon, Inc.Inventors: Rao S. Bezwada, Dennis D. Jamiolkowski
-
Patent number: 5645830Abstract: This invention relates to Lactobacillus, skim milk, Lactobacillus Growth Factor (LGF) and Lactobacillus compositions and methods of employing the compositions for preventing urogenital infections. More particularly, this invention relates to the ability of strains of hydrophobic or hydrophilic Lactobacillus to adhere to biomaterials, and intestinal, vaginal and uroepithelial cells, to resist the action of certain antimicrobial agents and to dominate the urogenital flora.Type: GrantFiled: September 19, 1994Date of Patent: July 8, 1997Assignee: Research Corporation Technologies, Inc.Inventors: Gregor Reid, Andrew W. Bruce
-
Patent number: 5645850Abstract: The present invention describes an aliphatic polyoxaamide polymer and blends thereof that may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The aliphatic polyoxaamide of the present invention have a first divalent repeating unit of formula I:[X--C(O)--C(R.sub.1) (R.sub.2)--O--(R.sub.3)--O--C(R.sub.1) (R.sub.2)--C(O)--] Iand a second repeating unit selected from the group of formulas consisting of:[--Y--R.sub.17 --].sub.T, I[--O--R.sub.5 --C(O)--].sub.B, and III([--O--R.sub.9 --C(O)].sub.P --O--) XIand combinations thereof, wherein X and Y are selected from the group consisting of --O-- and --N(R)--, provided both X and Y are not both --O-- and may be blended with a second polymer that is preferably biocompatable.Type: GrantFiled: August 7, 1996Date of Patent: July 8, 1997Assignee: Ethicon, Inc.Inventors: Rao S. Bezwada, Dennis D. Jamiolkowski
-
Patent number: 5643562Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: GrantFiled: March 15, 1995Date of Patent: July 1, 1997Assignee: Queen's University of KingstonInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Patent number: 5643582Abstract: This invention is a long acting moisturizer particularly suited for moisturizing the epithelia.Type: GrantFiled: September 22, 1994Date of Patent: July 1, 1997Assignee: SmithKline Beecham CorporationInventors: Balgopal Gangadharan, Marshall A. Hayward, Denise Lynne Ward
-
Patent number: 5637314Abstract: A method for treating atopic dermatitis, hayfever, asthma and pruritis that includes topical or systemic application of an effective amount of buspirone or a buspirone derivative or its pharmaceutically acceptable salt, other than a quaternary salt, optionally in a pharmaceutically-acceptable diluent or carrier.Type: GrantFiled: June 7, 1995Date of Patent: June 10, 1997Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Richard J. Sharpe, Kenneth A. Arndt, Stephen J. Galli
-
Patent number: 5624675Abstract: A method is disclosed for using a topical genital lubricant with a non-toxic, non-irritating zinc salt during sexual intercourse. The lubricant is spread upon one or more genital surfaces to create an anti-viral chemical barrier that reduces the risk of infection by the human immunodeficiency virus (HIV), the virus that causes AIDS. Suitable zinc salts include zinc acetate, zinc propionate, and other non-irritating water-soluble organic zinc salts that dissociate readily. When dissolved in water, these salts release divalent zinc ions (Zn.sup.++), which apparently can reduce HIV infectivity by at least three mechanisms. First, zinc ions form crosslinking bonds with cysteine and histidine residues in proteins (such as the gp120 protein of HIV), thereby "gluing" HIV particles to each other, to proteins in vaginal fluids, and to dead or dying cells that will soon be sloughed off from the genital surfaces. This reduces the ability of the HIV to infect susceptible cells.Type: GrantFiled: November 12, 1993Date of Patent: April 29, 1997Inventor: Patrick D. Kelly
-
Patent number: 5620701Abstract: Atopic eczema, breast pain or premenstrual syndrome are treated by administering to a person in need of same a composition containing at least 20% di-linoleoyl-mono-gamma-linolenyl glycerol by weight.Type: GrantFiled: February 14, 1996Date of Patent: April 15, 1997Assignee: Scotia Holdings PLCInventors: David F. Horrobin, Yung-Sheng Huang
-
Patent number: 5620698Abstract: The present invention describes aliphatic polyoxaesters containing amines and/or amido groups and blends thereof with other polymers that may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The aliphatic polyoxaesters of the present invention have a first divalent repeating unit of formula I:[O--C(O)--C(R.sub.1)(R.sub.2)--O--(R.sub.3)--O--C(R.sub.1)(R.sub.2)--C(O)-- ]Iand a second repeating unit of the formula:[--O--R.sub.12 --].sub.U, XVIand optionally a third repeating unit with a formula selected from the group consisting of:[--O--R.sub.4 --].sub.A, II[--O--R.sub.5 --C(O)--].sub.B, III([--O--R.sub.5 --C(O)].sub.P --O--).sub.L G XIand combinations thereof wherein R.sub.12 contains an internal amine or internal amide group.Type: GrantFiled: June 14, 1996Date of Patent: April 15, 1997Assignee: Ethicon, Inc.Inventors: Rao S. Bezwada, Dennis D. Jamiolkowski
-
Patent number: 5618550Abstract: A stable solution, cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.Type: GrantFiled: May 19, 1995Date of Patent: April 8, 1997Assignee: RBR HoldingsInventor: Perry A. Ratcliff
-
Patent number: 5618552Abstract: The present invention describes a new aliphatic polyoxaesters that is bioabsorbable and may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The invention also contemplates a process for producing these polyesters. The aliphatic polyoxaesters of the present invention have a first divalent repeating unit of formula I:[O--C(O)--C(R.sub.1)(R.sub.2)--O--(R.sub.3)--O--C(R.sub.1)(R.sub.2)--C(O)-- ]Iand a second repeating unit selected from the group of formulas consisting of:[--O--R.sub.4 --].sub.A, II[--O--R.sub.5 --C(O)--].sub.B, and III([--O--R.sub.5 --C(O)].sub.P --O--).sub.L G XIand combinations thereof.Type: GrantFiled: March 5, 1996Date of Patent: April 8, 1997Assignee: Ethicon, Inc.Inventors: Rao S. Bezwada, Dennis D. Jamiolkowski
-
Patent number: 5614208Abstract: Atopic eczema, breast pain or premenstrual syndrome are treated by administering to a person in need of same a composition containing at least 20% di-linoleoyl-mono-gamma-linolenyl glycerol by weight.Type: GrantFiled: February 14, 1996Date of Patent: March 25, 1997Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Yung-Sheng Huang
-
Patent number: 5607683Abstract: Antimicrobial metal-based compositions, which are photostable, non-staining, and which are easily absorbed into lipophilic matrices, contain silver cations, complexed by acyclic polyether polymers through the formation of a "host-guest relationship" where the acyclic polyether is the "host" and the silver cation is the "guest," wherein stabilization of this "host-guest relationship" is accomplished through the use of excess anions. The compositions are useful for topical treatment of infections caused by bacteria, fungus and viruses in humans and animals and for treating medical devices, foams and adhesives to impart infection-resistance.Type: GrantFiled: June 7, 1995Date of Patent: March 4, 1997Inventor: Christopher C. Capelli
-
Patent number: 5607687Abstract: The present invention describes a new aliphatic polyoxaesters and blends thereof that may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The invention also contemplates a process for producing these polyesters. The aliphatic polyoxaesters of the present invention have a first divalent repeating unit of formula I:[O--C(O)--C(R.sub.1)(R.sub.2)--O--(R.sub.3)--O--C(R.sub.1l)(R.sub.2)--C(O)- -] Iand a second repeating unit selected from the group of formulas consisting of:[--O--R.sub.4 --].sub.A, II[--O--R.sub.5 --C(O)--].sub.B, and III([--O--R.sub.5 --C(O)].sub.P --O--).sub.L G XIand combinations thereof. These aliphatic polyoxaesters may be blended with other polymers which are preferably biocompatable.Type: GrantFiled: March 5, 1996Date of Patent: March 4, 1997Assignee: Ethicon, Inc.Inventors: Rao S. Bezwada, Dennis D. Jamiolkowski
-
Patent number: 5599321Abstract: A sustained release bactericidal cannula or catheter for residence within a portion of a human body through which aqueous biological fluids can pass. The bactericidal cannula for catheter including a tube having an inner surface, defining and interior lumen, and an outer surface. The tube has a polymeric matrix and antibacterial agent residing within at least a portion of the polymeric matrix. The polymeric matrix includes cured silicon rubber and the antibacterial agent is a finely divided nitrofuran compound which is soluble in water and effective to prevent proliferation of certain bacteria in an otherwise growth supporting aqueous environment when dissolved in the aqueous environment to the limit of its solubility therein at 37.degree. C. The solubility of the nitrofuran compound is preferably about 0.2% by weight or less at a pH of about 6 and a temperature of about 25.degree. C.Type: GrantFiled: June 7, 1995Date of Patent: February 4, 1997Assignee: Rochester Medical CorporationInventors: Anthony J. Conway, Philip J. Conway, Richard D. Fryar, Jr.
-
Patent number: 5597579Abstract: The present invention describes an aliphatic polyoxaamide polymer and blends thereof that may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The aliphatic polyoxaamide of the present invention have a first divalent repeating unit of formula I:[X--C(O)--C(R.sub.1)(R.sub.2)--O--(R.sub.3)--O--C(R.sub.1)(R.sub.2)--C(O)-- ]Iand a second repeating unit selected from the group of formulas consisting of:[--Y--R.sub.17 --].sub.T, I[--O--R.sub.5 --C(O)--].sub.B, and II([--O--R.sub.9 --C(O)].sub.P --O--).sub.L G XIand combinations thereof, wherein X and Y are selected from the group consisting of --O-- and --N(R)--, provided both X and Y are not both --O-- and may be blended with a second polymer that is preferably biocompatable.Type: GrantFiled: March 5, 1996Date of Patent: January 28, 1997Assignee: Ethicon, Inc.Inventors: Rao S. Bezwada, Dennis D. Jamiolkowski
-
Patent number: 5595751Abstract: The present invention describes a new aliphatic polyoxaesters that is bioabsorbable and may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The invention also contemplates a process for producing these polyesters. The aliphatic polyoxaesters of the present invention have a first divalent repeating unit of formula I:[O--C(O)--C(R.sub.1) (R.sub.2)--O--(R.sub.3)--O--C(R.sub.1)(R.sub.2)--C(O)--] Iand a second repeating unit of the formula:[--O--R.sub.12 --].sub.U, XVIand optionally a third repeating unit with a formula selected from the group consisting of:[--O--R.sub.4 --].sub.A, II[--O--R.sub.5 --C(O)--].sub.B, III([--O--R.sub.5 --C(O)].sub.P,--O--).sub.L G XIand combinations thereof wherein R.sub.12 contains an internal amine or internal amide group.Type: GrantFiled: February 8, 1996Date of Patent: January 21, 1997Assignee: Ethicon, Inc.Inventors: Rao S. Bezwada, Dennis D. Jamiolkowski
-
Patent number: 5587175Abstract: Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.Type: GrantFiled: December 28, 1993Date of Patent: December 24, 1996Assignee: MDV Technologies, Inc.Inventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry
-
Patent number: 5558877Abstract: A medical device for insertion into a vaginal cavity comprising an elastomeric ring containing a compound selected from the group consisting of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl of 1 to 6 carbon atoms, R.sub.2 and R.sub.5 are individually alkyl of 1 to 6 carbon atoms, n is an integer from 2 to 6, R.sub.3 and R.sub.4 are individually aryl of 6 to 12 carbon atoms optionally substituted with 1 or 2 members of the group consisting of halogen and alkyl and alkoxy of 1 to 6 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts for the treatment and prevention of cancer.Type: GrantFiled: December 15, 1994Date of Patent: September 24, 1996Assignee: Roussel UclafInventors: Stephen A. Matlin, Andrew T. Wilkins
-
Patent number: 5554388Abstract: A composition for administration to the mucosa comprises a pharmacologically active compound and a polycationic substance. The polycationic substance is preferably DEAE-dextran or chitosan and the pharmacologically active compound is preferably insulin or calcitonin. The composition may be a solution, dispersion, powder or microspheres. Other enhancers, such as lysophosphatidylcholine, can be included if desired.Type: GrantFiled: December 14, 1993Date of Patent: September 10, 1996Assignee: Danbiosyst UK LimitedInventor: Lisbeth Illum
-
Patent number: 5554383Abstract: A veterinary method for clinically modifying the behavior of a household pet dog exhibiting a recognized type of canine affective aggression behavior is provided. The veterinary behavior modification method administers at least one selective serotonin reuptake inhibitor compound to the dog upon one or multiple occasions; and the administration of these compounds will modify clinically the canine affective aggression behavior of the household dog permanently or for an indefinite period of time. This veterinary behavior modification method can be usefully employed as an adjunct to conditioning approaches presently employed and will avoid the need for euthanasia in extreme behavioral circumstances.Type: GrantFiled: April 6, 1995Date of Patent: September 10, 1996Assignee: Trustees of Tufts CollegeInventor: Nicholas H. Dodman
-
Patent number: 5552150Abstract: A natural or synthetic glycerol oil which comprises at least 20% by weight, preferably at least 25% of di-linoleoyl-mono-gamma-linolenyl-glycerol (DLMG), is used to supplement foods, nutritional compositions and in skin and hair care compositions.Type: GrantFiled: November 30, 1993Date of Patent: September 3, 1996Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Yung-Sheng Huang
-
Patent number: 5545401Abstract: A virucidal, spermicidal vaginal gel consisting essentially of povidone iodine having a povidone to iodine ratio of about 15:1 or higher containing from about one percent to about twenty percent low molecular weight povidone having a molecular weight of about 20 kd or lower, the gel having a viscosity such that a conical body drawn from a body of the same does not visibly slump at 37C. for a period of at least one minute and a method of preventing sexual transmission of disease and preventing pregnancy using the same are disclosed.Type: GrantFiled: June 2, 1994Date of Patent: August 13, 1996Inventor: Edward Shanbrom
-
Patent number: 5543150Abstract: The present invention teaches that relatively low levels of serum progesterone, 1 to 6 ng/ml, may be used to prevent endometrial cancer. The vaginal delivery of progesterone using a cross-linked polycarboxylic polymer produces this low serum progesterone level while also providing the full secretory transformation of the endometrium, indicating the efficacy of the progesterone. Such low levels of serum progesterone will decrease the risk of breast cancer experienced by women undergoing hormone replacement therapy ("HRT") and minimize the potential of other undesirable progesterone associated side effects.Type: GrantFiled: September 15, 1993Date of Patent: August 6, 1996Assignee: Columbia Laboratories, Inc.Inventors: William J. Bologna, Howard L. Levine
-
Patent number: 5536506Abstract: A new composition and method for the improvement of gastrointestinal absorption and systemic utilization of nutrients and nutritional supplements, wherein the composition comprises an extract from the fruit of Piper containing a minimum of 98% of pure alkaloid piperine. The method comprises oral, topical, or parenteral administration of the compositions of the invention. A new process for the extraction and purification of piperine is also disclosed.Type: GrantFiled: February 24, 1995Date of Patent: July 16, 1996Assignee: Sabinsa CorporationInventors: Muhammed Majeed, Vladimir Badmaev, R. Rajendran
-
Patent number: 5529782Abstract: A dissolvable element containing an agent material is used for local administration of the agent material in an internal body area. The dissolvable element is made of dissolvable polymer material and/or complex carbohydrate material which are food grade materials and have selected dissolving properties, such that it remains in substantially solid form before use, and dissolves due to human body temperatures and moisture during use to release the agent material in a desired timed release and dosage. As a contraceptive, the dissolvable element is preferably a film made of polyvinyl alcohol, polyethylene oxide, hydroxypropyl methyl cellulose and/or carboxymethyl cellulose. The dissolvable element may be formed as a laminate of different film layers for compound release properties, or it may be ground into particles and incorporated in a tampon or suppository. The dissolvable element may be foamed as a means for increasing its dissolution rate.Type: GrantFiled: November 3, 1994Date of Patent: June 25, 1996Inventor: Robert Staab
-
Patent number: 5527532Abstract: A method of regulating repair in a physiological system following injury to the lumen of a tubular structure in that system, and of testing the effectiveness of regulatory agent, is presented. The method includes administering a modulator of cell or tissue growth to an extraluminal site adjacent the injured tissue. Administration of substances such as heparin over sustained, prolonged periods controls intimal hyperplasia and smooth muscle cell proliferation, even at doses that are insufficient to have such a beneficial effect if administered systemically. Bolus administration of such compounds at higher doses typically used to achieve systemic effects may have no effect or may even produce adverse effects.Type: GrantFiled: September 2, 1993Date of Patent: June 18, 1996Assignee: President and Fellows of Harvard CollegeInventors: Elazer R. Edelman, David H. Adams, Morris J. Karnovsky
-
Patent number: 5527534Abstract: A product for the administration of an active pharmaceutical agent via the vaginal canal comprising:(a) a sealed, air-tight package, enclosing therein;(b) a sponge impregnated with a liquid containing an effective amount of an active pharmaceutical agent, said liquid being present in an amount greater than that which is blocked within said sponge but less than the saturation value of said sponge such that when said sponge is inserted in the vaginal canal it will release liquid therefrom.Type: GrantFiled: October 21, 1993Date of Patent: June 18, 1996Assignee: Gynetech Laboratories, Ltd.Inventor: John Myhling
-
Patent number: 5518733Abstract: Cosmetic compositions providing a suitable medium for the development of beneficial endogenous flora, and including at least one oligosaccharide selected from the group consisting of gluco-oligosaccharides, fructo-oligosaccharides, .alpha.- and .beta.-galacto-oligosaccharides and mixtures thereof. Examples of compositions are liquid soap, body lotion, face cream and vaginal gel.Type: GrantFiled: December 23, 1993Date of Patent: May 21, 1996Assignee: BioeuropeInventors: Jean-Pierre H. G. Lamothe, Yves G. Marchenay, Pierre F. Monsan, Francois M. B. Paul, Vincent Pelenc
-
Patent number: 5512289Abstract: A personal lubricant composition containing an antiviral, alkylphenoxypolyethoxyethanol spermicide, a water soluble polymer gel matrix and a solubilizer which permits the spermicide to be compatible with the gel matrix. Preferably, a polyethoxylated compound such as polyethoxylated castor oil may be used.Type: GrantFiled: June 8, 1995Date of Patent: April 30, 1996Assignee: Johnson & Johnson Consumer Products, Inc.Inventors: Chung-Ye Tseng, Jonas Wang, Marilyn Hudson, Jue-Chen Liu
-
Patent number: 5492937Abstract: A carrier composition that is a liquid at or below room temperature forms a high viscosity layer or gel at body temperature, which comprises a water-soluble, nonionic cellulose ether having a cloud point not higher than 40.degree. C., a charged surfactant and optional additives in water. The carrier composition can be used for oral or local administration of a pharmacologically active substance to the skin, mucous membrane, the eye or a body cavity.Type: GrantFiled: May 21, 1993Date of Patent: February 20, 1996Assignee: Pharmacia ABInventors: Conny Bogentoft, Anders Carlsson